BioCentury
ARTICLE | Clinical News

CDX-301: Phase I data

November 12, 2012 8:00 AM UTC

Data from 18 healthy volunteers in an open-label, dose-escalation, U.S. Phase I trial showed that once-daily subcutaneous CDX-301 for 5-10 days was well tolerated up to 25 µg/kg. There was 1 dose-limi...